NutraIngredients-Asia Awards 2021

WATCH: Award winner Bened on its psychobiotics business plan in the US and biotherapeutic aspirations

By Tingmin Koe contact

- Last updated on GMT

Related tags: psychobiotics, Taiwan, stress

Psychobiotics specialist Bened Biomedical will be expanding its business in the US and is also dipping into the pharmaceutical realm by exploring the live biotherapeutic product (LBP) space, the firm’s CEO said.

In the recent NutraIngredients-Asia Awards, the Taiwan-based company took home the Probiotics Product of the Year with its psychobiotics product branded Pure Happiness.  

Containing its proprietary strain Lactobacillus plantarum​ PS128 for supporting relaxation and sleep, the probiotic product has been available in over 20 countries, even countries such as Africa.

CEO Frankie Cheng told NutraIngredients-Asia ​that over one million boxes of Pure Happiness have been sold in the past four to five years.

“The key consumer groups are made of sub-healthy population that experience insomnia, high stress, anxiety, or depression,” ​he said, adding that awareness of psychobiotics has increased due to the growing scientific evidence. 

To date, eight human clinical studies have been published on PS128 and its other probiotic strain Lactobacillus paracasei ​PS23 – which has been shown to reverse behaviours associated with anxiety and depression.

Asked the upcoming plans, Cheng said the company has been planning for a “more aggressive expansion” ​next year in the US, with a focus on the D2C model.

“We just completed a very successful series A fundraising and are poised to take on many more countries and channels to further increase market penetration.

“We are so psyched about our ever more aggressive expansion in 2022, especially in the United States. Indeed, we are planning to roll out our products based on the D2C model in the States,” ​he said.

In addition, he revealed that the company would be exploring the pharmaceutical space.

“We already started the work to turn our psychobiotics into a pharmaceutical LBP and have applied for investigational new drug development from the FDA.

“We firmly believe that with FDA’s new drug approval, we can potentially become the first-in-class psychobiotics therapeutic provider in the world.”

Watch the video to find out more.

Related news

Show more

Related products

AstaReal® – Formulating for Fitness & Mobility

AstaReal® – Formulating for Fitness & Mobility

AstaReal Co. Ltd | 06-Apr-2022 | Product Brochure

Declining muscle mass is part of the aging process. After age 30, our muscle mass decreases as much as 5% per decade and can cause serious health complications...

Related suppliers

Follow us

Products

View more

Webinars

Nutra Champions Podcast

Nutra Champions Podcast